Industry veteran joins Auxilium Pharmaceuticals

Adrian Adams succeeds Armando Anido at the US firm

Auxilium Pharmaceuticals, a specialist biopharmaceutical company based in Malvern, PA, US, has appointed Adrian Adams as chief executive and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down and has resigned as a member of the Board. Adams will also succeed him on the Board.

Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.

Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.

Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

You may also like

Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
Marketing

Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026

Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates
Manufacturing

Wilmington PharmaTech invests $50m into US small-molecule API manufacturing plant

The CRDMO will more than double the capacity in its current API reactor in Delaware, positioning itself to meet growing demand for US-based manufacturing
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now